Intuitive Surgical’s $450M antitrust deal

Intuitive Surgical (ISRG) has agreed to a proposed US$450 million settlement in an antitrust class action and has recorded a pre-tax charge of the same amount. The settlement addresses antitrust claims related to the company’s business practices and introduces additional legal and regulatory scrutiny. This settlement charge was recognized in the recent quarter and represents a sizable one-time cost that affects reported earnings. The proposed agreement also highlights ongoing attention to Intuitive Surgical’s competitive position in robotic surgery.

The antitrust case has drawn particular focus to the company’s service and accessory pricing. There is an ongoing discussion that further scrutiny of these pricing practices could pressure margins and affect the strength of Intuitive Surgical’s recurring revenue. This risk sits alongside the company’s extensive patent portfolio, which supports a business model in which branded instruments and accessories are not interchangeable with competing robotic systems.

Alongside the settlement charge, Intuitive Surgical delivered 22% revenue growth in the third quarter of 2026. The increase was supported by rising use of its da Vinci 5 surgical system and its Ion platform. Despite the sizable legal charge, the company’s operating trends in minimally invasive robotic procedures continued to expand. This combination of strong top-line performance and a large, non-recurring legal expense defines the latest reporting period.

The company had set aside US$450 million for the proposed settlement roughly three weeks before 12 November, aligning the balance sheet impact with the anticipated resolution of the antitrust class action. This provision, together with the underlying growth in procedure volumes and installed systems, frames the current financial profile. Investors are weighing whether the settlement meaningfully alters the long-term economics of Intuitive Surgical’s razor-blade style revenue mix across instruments, systems, and services.

Intuitive Surgical’s stock performance reflects both recent recovery and earlier weakness. The shares are up 12.15% over the past 90 days and 6.15% over the past 30 days, yet they are down 19.92% on a year-to-date basis. Over the past year, total shareholder return has declined 21.35%, while the three-year total shareholder return stands at 54.32%. These figures highlight a stronger longer-run record contrasted with more recent volatility around legal and valuation concerns.

Valuation assessments point in different directions. One discounted cash flow model estimates a fair value of US$471.47, suggesting the shares trade modestly below the value of projected future cash flows. A separate narrative from a group of nine investors assigns a fair value of US$630.48, implying the stock is 29% undervalued. At the same time, the shares trade at a price-to-earnings ratio of 52.8 times, compared with 26 times for the broader US medical equipment group and 38.1 times as a reference fair ratio.

Analyst coverage has remained active around these developments. The move underscores confidence in the company’s fundamentals despite the legal overhang.

There has also been recent insider-related share activity. The trust of board member Gary S. Guthart sold shares in November, and director Craig H. Barratt exercised options and sold shares on the same day. Both transactions were executed under Rule 10b5-1 trading plans, as disclosed in filings submitted on 5 November. These planned trades add another data point for investors evaluating governance, insider behavior, and the overall risk-reward profile following the antitrust settlement agreement.